论文部分内容阅读
目的观察阿昔莫斯胶囊对冠心病PCI术后血脂的调节作用。方法将符合纳入标准的220例PCI术后患者按照数字表法随机分为治疗组与对照组。两组患者均于PCI术后给予低分子肝素钙、阿司匹林肠溶片、氯吡格雷、辛伐他汀片。治疗组在此基础上加用阿昔莫期胶囊,250mg/次,每日2次。两组患者均以治疗1个月为1个疗程,治疗1个疗程后观察疗效。结果治疗后显效率治疗组为46.36%,对照组为27.27%,两组相比差异有统计学意义(P<0.05)。有效率治疗组为73.62%,对照组为57.28%,两组相比较差异有统计学意义(P<0.05)。两组患者治疗后全血黏度、血浆黏度、红细胞组织、纤维蛋白原,治疗组与对照组相比较,差异有统计学意义(P<0.05)。两组治疗前血脂各项指标的比较,差异无统计学意义(P>0.05)。两组治疗后TC、TG及LDL-C均明显下降,HDL-C明显上升,与治疗前相比差异有统计学意义(P<0.05)。治疗组治疗后TC、TG及LDL-C下降、HDL-C上升较对照组明显(P<0.05)。结论阿昔莫斯用于冠心病PCI术后可明显降低血浆中TC、TG及LDL-C的含量,并可升高HDL-C含量。
Objective To observe the effect of aciposome on the regulation of blood lipids in patients with coronary heart disease after PCI. Methods A total of 220 cases of PCI patients who met the inclusion criteria were randomly divided into treatment group and control group according to digital table method. Both groups were given low molecular weight heparin, aspirin enteric-coated tablets, clopidogrel and simvastatin tablets after PCI. On the basis of the treatment group, acyclovir capsule was added at 250 mg twice daily. Two groups of patients were treated for 1 month as a course of treatment, after a course of treatment observed the effect. Results After treatment, the effective rate was 46.36% in the treatment group and 27.27% in the control group. There was significant difference between the two groups (P <0.05). Effective treatment group was 73.62%, control group was 57.28%, the difference between the two groups was statistically significant (P <0.05). After treatment, the whole blood viscosity, plasma viscosity, erythrocyte tissue, fibrinogen in treatment group and control group were significantly different (P <0.05). There was no significant difference in each index between two groups before treatment (P> 0.05). The levels of TC, TG and LDL-C in both groups were significantly decreased and HDL-C significantly increased after treatment, with statistical significance (P <0.05). After treatment, TC, TG and LDL-C decreased and HDL-C increased in treatment group compared with control group (P <0.05). Conclusion The use of oximeprosy for coronary heart disease (PCI) can significantly reduce the content of TC, TG and LDL-C in plasma and increase the content of HDL-C.